Growth Metrics

Vanda Pharmaceuticals (VNDA) Free Cash Flow (2016 - 2025)

Vanda Pharmaceuticals' Free Cash Flow history spans 16 years, with the latest figure at -$29.5 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 1353.42% to -$29.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$110.4 million, a 579.76% decrease, with the full-year FY2025 number at -$110.4 million, down 579.76% from a year prior.
  • Free Cash Flow hit -$29.5 million in Q4 2025 for Vanda Pharmaceuticals, up from -$31.8 million in the prior quarter.
  • Over the last five years, Free Cash Flow for VNDA hit a ceiling of $31.8 million in Q1 2023 and a floor of -$33.6 million in Q1 2025.
  • Historically, Free Cash Flow has averaged -$965100.0 across 5 years, with a median of $970000.0 in 2022.
  • Biggest five-year swings in Free Cash Flow: soared 808.05% in 2021 and later crashed 1353.42% in 2025.
  • Tracing VNDA's Free Cash Flow over 5 years: stood at $26.5 million in 2021, then plummeted by 65.43% to $9.2 million in 2022, then crashed by 143.54% to -$4.0 million in 2023, then soared by 49.03% to -$2.0 million in 2024, then crashed by 1353.42% to -$29.5 million in 2025.
  • Business Quant data shows Free Cash Flow for VNDA at -$29.5 million in Q4 2025, -$31.8 million in Q3 2025, and -$15.6 million in Q2 2025.